Riskpilot← Back to searchSign inGet full accessOriGen Biomedical AB
ABIn liquidationOrg 5567106132Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20060 employees
Revenue 2020
SEK 26K
-91% vs 2019
EBITDA margin
-188.5%
-2550% vs 2019
Equity ratio
98.5%
Financial strength
Net profit 2020
SEK 870K
+9567% vs 2019
| Revenue | SEK 26K | -91% |
| EBITDA | SEK -49K | -2550% |
| Net profit | SEK 870K | +9567% |
| Total assets | SEK 1M | +254% |
| Equity | SEK 1M | +264% |
| Employees | 0 | — |
Legal name
OriGen Biomedical AB
Org number
5567106132
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
11 september 2006
Share capital
SEK 0
Employees
0
VAT registered
No
Audit selected
No
Last report
2020-12-31
Financial year
January – December
Company purpose
Bolagets verksamhet skall utgöras av produktion av handel med och utveckling av medicintekniska produkter samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenue | 775 | 461 | 507 | 276 | 26 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 22 | 4 | 355 | 2 | −49 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 22 | 4 | 355 | 2 | −49 |
| Net financials | −8 | −3 | — | 7 | 919 |
| Profit before tax | 14 | 1 | 355 | 9 | 870 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 14 | 1 | 355 | 9 | 870 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Total assets | 247 | 243 | 582 | 289 | 1 022 |
| Equity | 212 | 214 | 569 | 277 | 1 007 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 34 | 29 | 13 | 12 | 15 |
| Total debt | 34 | 29 | 13 | 12 | 15 |
EBITDA margin
-188.5%
This company
15.8%
Market median
-1293% vs market
20162020
Equity ratio
98.5%
This company
38.2%
Market median
+158% vs market
20162020
Return on equity
86.4%
This company
18.4%
Market median
+370% vs market
20162020
Net profit margin
3346.2%
This company
8.1%
Market median
+41211% vs market
20162020
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
20162020
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20162020
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
LT Liquidator | Liquidator | 2020 |
IL Liquidator | Liquidator | 2020 |
| Former (1) | ||
IL | Liquidator | 2022 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
| Deputy Board Member | 2020 – 2021 | |
| Board of Directors | 2020 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of OriGen Biomedical AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Leif Tommie Rogert Rasmusson | Liquidator | 0 companies |
| Irene Lilian B Lundstedt Rasmusson | Liquidator | 0 companies |
| Irene Lilian Birgitta Lundstedt Rasmusson | Liquidator | 0 companies |
| Marie Madeleine Johnson | Deputy Board Member | 0 companies |
| Bo Allan Johnson | Board of Directors | 0 companies |